Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid

Abstract: A method for stabilizing an arylcarboxylic acid, which comprises adding a heterocyclic base to the arylcarboxylic acid or a pharmacologically acceptable salt thereof, a stabilizer thereof and an aqueous solution containing a stabilized arylcarboxylic acid. According to the stabilization method of the present invention, arylcarboxylic acid and pharmacologically acceptable salts thereof, particularly pranoprofen, can be stabilized at every temperature range, particularly at lower temperatures, thereby making the production of an aqueous solution to be used as an eye drop, nasal drop, ear drop and the like possible.

Description: The present invention relates to a method for stabilizing arylcarboxylic acid, which is an acidic compound and which has an antiinflammatory activity, or a pharmacologically acceptable salt thereof. BACKGROUND OF THE INVENTION Arylcarboxylic acid and pharmacologically acceptable salts thereof have been known to be extremely superior antiinflammatory agents. However, said arylcarboxylic acids, particularly pranoprofen, diclofenac and bromfenac, are associated with a problem that they become unstable in an aqueous solution. Arylcarboxylic acid and pharmacologically acceptable salts thereof have been also known to be stabilized by adding an antioxidant, by adjusting the pH, concentration and ionic strength thereof, by shutting out the light, and the like. These methods, nevertheless, cannot provide sufficient stability at lower temperatures. Thus, an aqueous solution has not been provided which contains an arylcarboxylic acid or a pharmacologically acceptable salt thereof, particularly pranoprofen, dicrofenac or bromfenac, and which has sufficient stability at lower temperatures. While WO9632941 A1 discloses pranoprofen combined with an organic amine, it does not disclose the heterocyclic base to be used in the present invention. JP 08333246 (PATENT ABSTRACTS OF JAPAN vol 1997, no. 04) discloses a method for stabilizing an arylcarboxylic acid, which comprises adding a purine base. SUMMARY OF THE INVENTION It is therefore an object of the present invention to provide a method for stabilizing an arylcarboxylic acid and a pharmacologically acceptable salt thereof. According to the present invention, it has now been found that the addition of a pyridonecarboxylic acid to an arylcarboxylic acid or a pharmacologically acceptable salt thereof leads to successful stabilization thereof, particularly pranoprofen, at every temperature range, particularly at low temperatures. Thus, the present invention provides the following. A method for stabilizing an arylcarboxylic acid or a pharmacologically acceptable salt thereof in an aqueous solution, which comprises adding (a) a pyridonecarboxylic acid of the formula (IV): wherein. X is a carbon atom or a nitrogen atom; and R 12 , R 13 , R 14 and R 15 are the same or different and each is a hydrogen atom; a halogen; a carboxyl group, an optionally substituted C 1 -C 6 alkyl group; an optionally substituted C 3 -C 9 cycloalkyl group; an acyl group selected from the group consisting of formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, benzoyl, naphthoyl, toluoyl and salicyloyl, which may be substituted by C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 alkylthio, C 1 -C 3 alkylamino, cyclo(C 3 -C 6 )alkyl, cyclo(C 3 -C 6 )alkenyl, halogen, amino, amino protecting group, hydroxy, protected hydroxy cyano, nitro, carboxy, protected carboxy, sulfo, sulfamoyl, imino, oxo, amino(C 1 -C 2 )alkyl, carbamoyloxy or hydroxy(C 1 -C 3 )alkyl; an optionally substituted aryl group or an optionally substituted heterocyclic group; wherein R 12 and R 13 optionally form a 4- to 6-membered heterocyclic group with the adjacent nitrogen atom and X, and R 14 and R 15 optionally form a 4- to 6-membered heterocyclic group with the adjacent carbon atom, provided that when X is a nitrogen atom, R 13 is void, or (b) cinoxacin or sparfloxacin, or a pharmacologically acceptable salt thereof, to an arylearboxylic acid of the formula (I) L 1 -R 1 COOH wherein L 1 is an optionally substituted heterocyclic group or aryl group having not more than 14 carbon atoms; and R 1 is an optionally substituted alkyl group having not more than 4 carbon atoms or a single bond, or a pharmacologically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION The stabilizing method of the present invention comprises the addition of a stabilizer containing a pyridonecarboxylic acid as an active ingredient to an arylcarboxylic acid, which is an acidic compound and which has an antiinflammatory activity, or a pharmacologically acceptable salt thereof. For example, a pyridonecarboxylic acid is added to an arylcarboxylic acid or a pharmacologically acceptable salt thereof. To be specific, an arylcarboxylic acid and a pyridonecarboxylic acid are dissolved in water and the pH thereof is adjusted with boric acid, acetic acid, phosphoric acid, which is followed by lyophilization where necessary. While the pH varies depending on the kind of arylcarboxylic acid, it is generally 5-9, preferably about 6-8. Said pyridonecarboxylic acid may be any as long as it has the formula (IV) as defined above. The alkyl of the "optionally substituted C 1 -C 6 alkyl group" may be a linear or branched one, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, and neohexyl. The cycloalkyl of the "optionally substituted C 3 -C 9 cycloalkyl group" is exemplified by cyclopropyl, cyclobutyl, cyalopentyl, cyclohexyl, and cycloheptyl. The substituents of the above-mentioned C 1 -C 6 alkyl group and C 3 -C 9 cycloalkyl group include C 1 -C 3 alkyl group, and halogen. The lower acyl of the "optionally substituted lower acyl group" may be, for example, formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, benzoyl group, naphthoyl group, toluoyl group, and salicyloyl group. The above-mentioned acyl may be substituted by suitable substituents which may be the same or different, such as lower alkyl (e.g., methyl, ethyl, propyl); lower alkoxy (e.g., methoxy, ethoxy, propoxy); lower alkylthio (e.g., methylthio, ethylthio); lower alkylamino (e.g., methylamino, ethylamino, and propylamino); cyclo(lower)alkyl such as cyclo(C 3 -C 6 )alkyl (e.g., cyclopentyl, and cyclohexyl); cyclo(lower)alkenyl such as cyclo(C 3 -C 6 )alkenyl (e.g., cycloxenyl, and cyclohexadienyl); halogen (e.g., fluorine, chlorine, bromine and iodine); amino; amino protecting group; hydroxy; protected hydroxy; cyano; nitro; carboxy; protected carboxy; sulfo; sulfamoyl; imino; oxo; amino(lower)alkyl (e.g., aminomethyl, aminoethyl), carbamoyloxy, hydroxy(lower)alkyl (e.g., hydroxymethyl, 1- or 2-hydroxyethyl, 1- or 2- or 3-hydroxypropyl). The aryl of the "optionally substituted aryl group" is exemplified by phenyl, and naphthyl, with preference given to naphthyl. The heterocyclic group of the optionally substituted heterocyclic group may contain, besides the carbon atom, at least one hetero atom selected from the group consisting of a nitrogen atom, sulfur atom and oxygen atom, as the atom constituting the ring, and may be a saturated or unsaturated, heteromonocyclic or heteropolycyclic group. The preferable heterocyclic groups are the following: 3- to 6-membered unsaturated heteromonocyclic group having 1 to 4 nitrogen atoms, such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, and 2H-1,2,3-triazolyl), tetrazolyl (e.g., 1H-tetrazolyl, and 2H-tetrazolyl), triazinyl (e.g., 1,2,4-triazinyl); 3- to 7-membered saturated heteromonocyclic group having 1 to 4 nitrogen atoms, such as pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, homopiperazinyl; saturated heteropolycyclic group having 1 to 4 nitrogen atoms, such as quinuclidinyl; unsaturated heteropolycyclic group having 1 to 5 nitrogen atoms, such as indolyl, isoindolyl, 3H-indolyl, indolizinyl, benzoimidazolyl, quinolyl, isoquinolyl, indazolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl), pteridinyl, carbazolyl, phenanthrinidyl, acridinyl, and perimidyl; 3- to 6-membered unsaturated heteromonocyclic group having 1 to 3 nitrogen atoms and 1 or 2 oxygen atoms, such as oxazolyl, isooxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl); 3- to 6-membered saturated heteromonocyclic group having 1 to 3 nitrogen atoms and 1 or 2 oxygen atoms, such as morpholinyl, and sydnolyl; unsaturated condensed heterocyclic group having 1 to 3 nitrogen atoms and 1 or 2 oxygen atoms, such as benzofurazanyl, benzoxazolyl, benzoxazinyl, and benzoxadiazolyl; 3- to 6-membered unsaturated condensed heterocyclic group having 1 to 3 nitrogen atoms and 1 or 2 sulfur atoms, such as thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, and 1,2,5-thiadiazolyl). 3- to 6-membered saturated heteromonocyclic group having 1 to 3 nitrogen atoms and 1 or 2 sulfur atoms, such as thiazolidinyl; unsaturated condensed heterocyclic group having 1 to 3 nitrogen atoms and 1 or 2 sulfur atoms, such as benzothiazolyl, and benzothiadiazolyl; 3- to 6-membered unsaturated heteromonocyclic group having 1 oxygen atom, such as furyl, and pyranyl; 3- to 6-membered unsaturated heteromonocyclic group having 1 or 2 sulfur atoms, such as thienyl, and dihydrothienyl; unsaturated condensed heterocyclic group having 1 or 2 sulfur atoms, such as benzothienyl. The aryl group and heterocyclic group are optionally substituted by one or more substituents selected from the group consisting of hydroxyl group, halogen atom, aliphatic alkyl group, aromatic alkyl group, aliphatic carboxylic acid group, aromatic carboxylic acid group, aliphatic carboxylate group, aromatic carboxylate group, aliphatic ether group, aromatic ether group, aliphatic alcohol group, aromatic alcohol group, aliphatic aldehyde group, aromatic aldehyde group, aliphatic amino group, aromatic amino group, which are optionally substituted by halogen atom. The 4- to 6-membered ring formed by R 12 and R 13 with the adjacent nitrogen atom and X, and the 4- to 6-membered heterocyclic ring formed by R 14 and R 15 with the adjacent carbon atom may be, for example, thienyl group, furyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, thiazolyl group, isothiazolyl group, oxazolyl group, isooxazolyl group, oxadiazolyl group, thiadiazolyl group, triazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, triazinyl group, dithiazolyl group, dioxolanyl group (e.g., 1,3-dioxolanyl group), dithiolyl group, pyrrolidinyl group, thiaziadinyl group, dithiaziadinyl group, morpholinyl group, oxazinyl group, thiazinyl group, piperazinyl group, piperidinyl group, pyranyl group, and thiopyranyl group. Examples of the pyridonecarboxylic acid include norfloxacin: [1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid], ofloxacin: [(±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid], enoxacin: [1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid], cinoxacin: [1-ethyl-1,4-dihydro-4-oxo-[1,3]-dioxolo[4,5-g]cinnoline-3-carboxylic acid], ciprofloxacin: [1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid], sparfloxacin: [5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid], tosufloxacin: [(±)-7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1-naphthyridine-3-carboxylic acid], fleroxacin: [6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid], levofloxacin: [(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid], lomefloxacin: [1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid], 5,8-dihydro-8-ethyl-2-(1-piperazinyl)-5-oxopyrido[2,3-d]pyrimidinecarboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-7-(3-methylamino-1-pyrrolidinyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, and 7-(3-amino-3-methyl-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, and salts thereof. The pharmacologically acceptable salts of pyridonecarboxylic acid include, for example, acid addition salts with inorganic acid such as hydrochloric acid, sulfuric acid, and phosphoric acid, organic acid such as acetic acid, lactic acid, succinic acid, methanesulfonic acid, maleic acid, malonic acid, and gluconic acid, or amino acid such as aspartic acid, and glutamic acid; metal salts such as sodium salt, and potassium salt. The arylcarboxylic acid to be used for the stabilization of the present invention may be any compound as long as it has the following formula (I): L 1 -R 1 COOH wherein L 1 is an optionally substituted heterocyclic group or aryl group having not more than 14 carbon atoms; and R 1 is an optionally substituted alkyl group having not more than 4 carbon atoms or a single bond. The heterocyclic group in the optionally substituted heterocyclic group having not more than 14 carbon atoms may be exemplified by those mentioned above, and the substituents of said heterocyclic group are also exemplified by those mentioned above. The aryl of the "optionally substituted aryl group having not more than 14 carbon atoms" may be exemplified by those mentioned above, and the substituents of said aryl group are also exemplified by those mentioned above. The alkyl of the "optionally substituted alkyl group having not more than 4 carbon atoms" may be, for example, a linear or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl. Examples of the arylcarboxylic acid include naphthoic acid-related compounds, salicylic acid-related compounds, phenylacetic acid-related compounds, pyrazolone-related compounds, anthranilic acid-related compounds, indoleacetic acid-related compounds, fenclozic acid-related compounds and salts thereof. Examples of the naphthoic acid-related compounds include 2-naphthoic acid, 2-naphthylacetic acid, and 2-naphthoxyacetic acid. Examples of the salicylic acid-related compounds include salicylic acid, aspirin, flufenisal, ethenzamide, and benorylate. Examples of the phenylacetic acid-related compounds include ibufenac, alclofenac, flurbiprofen, ketoprofen, naproxen, ibuprofen, bromfenac, pranoprofen, namoxylate, and fenoprofen. Examples of the pyrazolone-related compounds include aminopyrine phenylbutazone, azapropazone, and cinopentazone. Examples of the anthranilic acid-related compounds include mefenamic acid, niflumic acid, diclofenac, metiazihic acid, protizinic acid, clonixin, flufenamic acid, and ketoprofen. Examples of the indoleacetic acid-related compounds include indomethacin, and intrazole. The amount of the heterocyclic base to be added to the arylcarboxylic acid or a pharmacologically acceptable salt thereof is preferably 0.001-5 parts by weight per 100 parts by weight of the arylcarboxylic acid or pharmacologically acceptable salt thereof. The stabilizer of the arylcarboxylic acid and a pharmacologically acceptable salt thereof contains a heterocyclic base as an active ingredient, and the amount thereof is about the same as the amount mentioned above. The solvent to be used for the aqueous solution of the present invention may be, for example, purified water, particularly distilled water for injection. The concentration of the active ingredient of the aqueous solution, i.e. arylcarboxylic acid, can be markedly increased by a heterocyclic base, preferably to 0.1-10 (w/v)%. The heterocyclic base to be used for the aqueous solution of the present invention may be those mentioned above. Said aqueous solution may contain various additives as appropriate, such as buffer, isotonizing agent, solubilizer, antiseptic, thickener, chelating agent, and aromatic. Examples of the buffer include phosphate buffer, borate buffer, citrate buffer, tartrate buffer, acetate buffer, and amino acid. Examples of the isotonizing agent include sugars such as sorbitol, glucose, and mannitol, polyhydric alcohols such as glycerol, and propylene glycol, salts such as sodium chloride. Examples of the solubilizer include non-ionic surfactants such as polyoxyethylenesorbitan monoolate, polyoxyethyleneoxystearic acid triglyceride, polyethylene glycol, and polyoxyethylene hydrogenated castor oil. Examples of the antiseptic include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride, p-hydroxybenzoates such as methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, and butyl p-hydroxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid, salts thereof, thimerosal, chlorobutanol, and sodium dehydroacetate. Examples of the thickener include polyvinylpyrrolidone, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, and salts thereof. Examples of the chelating agent include sodium edetate, and citric acid. Examples of the aromatic include 1-menthol, borneol, camphor, and eucalyptus oil. The aqueous solution of the present invention is used as an eye drop, nasal drop or ear drop. When it is used as an eye drop, its pH is generally adjusted to 3.5-8.5, preferably 6-7, when it is used as a nasal drop, its pH is generally adjusted to 3.5-8.5, preferably about 6-7, and when it is used as an ear drop, its pH is generally adjusted to 3.5-8.5, preferably 6-7. While the method for producing the aqueous solution of the present invention varies depending on the kind of a desired solution, a known method can be used to produce such aqueous solution. When the aqueous solution of the present invention is used as an eye drop, for example, the dose thereof need only be sufficient to effectively suppress an inflammation in the eye, and may vary according to symptoms, the kind of inflammation, the patients (human or animal) in need of said solution. A typical dose is 20-200 µL, preferably 50-100 µL, which may be administered 1 to 12 times a day. The present invention is described in more detail by way of Examples and Experimental Examples. Experimental Example 1 : Stabilization of pranoprofen - 1 Solutions (Examples 1-3 below) of 0.5 w/v% pranoprofen were respectively charged in 5 ml colorless glass ampoules, and allowed to stand at 80°C for 1 week and 2 weeks, at 60°C for 1 week and 2 weeks, and at 4°C for 1 week. The percentage of residual pranoprofen in the ampoules after standing was determined by high performance liquid chromatography. The results are shown in Table 1. The values in the Table are relative to the amount of pranoprofen when it was prepared, which was taken as 100. temperature-period residual pranoprofen (%) w/o addition norfloxacin ofloxacin enoxacin 80°C -1W 95.4 91.0 99.5 96.7 80°C - 2W 93.0 85.0 100.4 95.9 60°C -1W 98.7 98.0 99.8 99.2 60°C - 2W 98.5 93.8 98.8 98.4 4°C -1W 87.5 99.8 99.9 99.2 As is evident from the results shown in Table 1, pranoprofen was markedly stabilized against heat by the addition of of loxacin, and enoxacin. The decomposition of pranoprofen which occurs at low temperatures was significantly suppressed by norfloxacin, of loxacin, and enoxacin. Example 1 An eye drop having the following formulation was prepared. pranoprofen 1.0 g norfloxacin 0.6 g boric acid 3.2 g sodium hydroxide appropriate amount sterile purified water appropriate amount total amount 200 ml (pH 7) Example 2 An ear drop having the following formulation was prepared. pranoprofen 1.0 g ofloxacin 0.6 g boric acid 3.2 g sodium hydroxide appropriate amount sterile purified water appropriate amount total amount 200 ml (pH 7) Example 3 A nasal drop having the following formulation was prepared. pranoprofen 1.0 g enoxacin 0.6 g phosphoric acid 0.1 g sodium hydroxide appropriate amount sterile purified water appropriate amount total amount 200 ml (pH 7) Example 4 An eye drop having the following formulation was prepared. pranoprofen 0.1 g ofloxacin 0.3 g boric acid 1.8 g sorbic acid 0.1 g sterile purified water appropriate amount total amount 100 ml (pH 7) Example 5 An eye drop having the following formulation was prepared. pranoprofen 0.1 g enoxacin 0.3 g boric acid 1.8 g benzalkonium chloride 0.002 g sodium citrate 0.1 g sterile purified water appropriate amount total amount 100 ml (pH 7) Example 6 An ear drop having the following formulation was prepared. pranoprofen 1.0 g of loxacin 0.6 g phosphoric acid 0.1 g sodium hydroxide appropriate amount sterile purified water appropriate amount total amount 200 ml (pH 7) According to the stabilization method of the present invention, arylcarboxylic acid and pharmacologically acceptable salts thereof, particularly pranoprofen, can be stabilized at every temperature range, particularly at lower temperatures, thereby making the production of an aqueous solution to be used as an eye drop, nasal drop, and ear drop possible.

Claims: A method for stabilizing an arylcarboxylic acid or a pharmacologically acceptable salt thereof in an aqueous solution, which comprises adding (a) a pyridonecarboxylic acid of the formula (IV): wherein X is a carbon atom or a nitrogen atom; and R 12 , R 13 , R 14 and R 15 are the same or different and each is a hydrogen atom; a halogen; a carboxyl group, an optionally substituted C 1 -C 6 alkyl group; an optionally substituted C 3 -C 9 cycloalkyl group; an acyl group selected from the group consisting of formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, benzoyl, naphthoyl, toluoyl and salicyloyl, which may be substituted by C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 alkylthio, C 1 -C 3 alkylamino, cyclo(C 3 -C 6 )alkyl, cyclo(C 3 -C 6 )alkenyl, halogen, amino, amino protecting group, hydroxy, protected hydroxy cyano, nitro, carboxy, protected carboxy, sulfo, sulfamoyl, imino, oxo, amino(C 1 -C 2 )alkyl, carbamoyloxy or hydroxy(C 1 -C 3 )alkyl; an optionally substituted aryl group or an optionally substituted heterocyclic group; wherein R 12 and R 13 optionally form a 4- to 6-membered heterocyclic group with the adjacent nitrogen atom and X, and R 14 and R 15 optionally form a 4- to 6-membered heterocyclic group with the adjacent carbon atom, provided that when X is a nitrogen atom, R 13 is void, or (b) cinoxacin or sparfloxacin, or a pharmacologically acceptable salt thereof, to an arylcarboxylic acid of the formula (I): L 1 -R 1 COOH wherein L 1 is an optionally substituted heterocyclic group or aryl group having not more than 14 carbon atoms; and R 1 is an optionally substituted alkyl group having not more than 4 carbon atoms or a single bond, or a pharmacologically acceptable salt thereof. The method of claim 1, wherein the pyridonecarboxylic acid is at least one compound selected from the group consisting of lomefloxacin, norfloxacin, ofloxacin, enoxacin, ciprofloxacin, tosufloxacin, fleroxacin and levofloxacin. The method of claim 1, wherein the arylcarboxylic acid is at least one compound selected from the group consisting of ibuprofen, diclofenac, 2-naphthoic acid, 2-naphthylacetic acid, bromfenac, pranoprofen, salicylic acid, aspirin, flufenisal, ibufenac, alclofenac, flurbiprofen, ketoprofen, naproxen, mefenamic acid, niflumic acid, metiazinic acid, protizinic acid, clonixin, indomethacin and fenclozic acid. The method of claim 1, wherein the pyridonecarboxylic acid is added in a proportion of 0.001-5 parts by weight per 100 parts by weight of the arylcarboxylic acid.

Inventors: SHIROU SAWA, SHIROU, SAWA
Applicants: SENJU PHARMA CO, SENJU PHARMACEUTICAL CO., LTD.
Application year: 1998
Main classification: A61K45
IPC codes: A61K9, A61K47, A61K45